What's Happening?
Pulse Biosciences, Inc., a company specializing in bioelectric medicine, has announced its participation in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas, Nevada. The company's management
is scheduled to present on May 13, 2026, at 4:35 pm PT. Pulse Biosciences is known for its proprietary nPulse technology, which uses nanosecond pulsed field ablation (nsPFA) energy to non-thermally clear cells while sparing adjacent non-cellular tissue. This technology is being developed for applications in treating atrial fibrillation and other medical conditions. The presentation will be available via a live and recorded webcast on the company's investor website.
Why It's Important?
Pulse Biosciences' participation in the BofA Securities Healthcare Conference highlights the company's ongoing efforts to advance its innovative nPulse technology. This technology has the potential to significantly impact healthcare by providing new treatment options for conditions like atrial fibrillation. The conference serves as a platform for Pulse Biosciences to showcase its advancements to investors and industry stakeholders, potentially attracting new investment and partnerships. The development of non-thermal cell clearing technology could lead to improved patient outcomes and reduced healthcare costs, making it a significant advancement in the field of bioelectric medicine.
